Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Brendan M. Weiss, MD

Brendan M. Weiss, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Weiss is a Penn Medicine employed physician.

Clinical Specialties

Specialty:

  • Medicine
    • Hematology
    • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 2004
  • Internal Medicine, 2001
  • Medical Oncology, 2006

Clinical Expertise:

  • Autologous Stem Cell Transplantation
  • Blood Cancer
  • Bone Marrow Transplant
  • Cardiac Amyloidosis
  • Multiple Myeloma
  • Waldenstrom Macroglobulinemia (WM)

Description of Clinical Expertise

I am interested in the evaluation and management of patients with multiple myeloma, AL amyloidosis, and Waldenstrom's macroglobulinemia. I have a particular interest in the evaluation and management of myeloma precursor states, monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). In addition, I am interested in the other paraprotein-associated diseases such as monoclonal gammopathy of renal significance (MGRS), paraprotein associated neuropathy, cryoglobulinemia, POEMS syndrome and others.

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Uniformed Services University of the Health Sciences
Residency: Brooke Army Medical Center
Fellowship: Walter Reed Military Medical Center

Memberships

American Society of Clinical Oncology, National American Society of Hematology, National Center for International Bone Marrow Transplantation Research, International International Kidney and Monoclonal Gammopathy Research Group, International International Myeloma Working Group, International International Society of Amyloidosis, International

Hospital Affiliation

Dr. Weiss is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

I am a hematologist-oncologist with a specific research and clinical interest in plasma cell disorders and related dysproteinemias: multiple myeloma, immunoglobulin light chain (AL) amyloidosis, and Waldenstrom’s macroglobulinemia.

I also lead the multi-disciplinary Penn Amyloidosis Program. This is a cross-disciplinary program involving clinicians with expertise in amyloidosis from cardiology, nephrology, pathology and other disciplines.

I am involved in clinical, translational and epidemiologic research throughout the spectrum of plasma cell disorders. My primary research focus is on the myeloma precursor states: monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). I have previously established that both multiple myeloma (Weiss Blood 2009) and AL amyloidosis (Weiss J Clin Oncol 2014) have precursor states that are detectable for many years prior to diagnosis. I have also validated biomarkers for ultra-high risk SMM (Waxman Leukemia 2014) that have contributed to changing the diagnostic criteria for multiple myeloma requiring treatment (Rajkumar Lancet Oncol 2014).

I am currently performing trials to develop and test novel biomarkers for progression in the myeloma precursor states (MGUS and SMM). I am also participating in trials of early intervention in high risk SMM.

I am also conducting trials of novel agents for AL amyloidosis and relapsed and refractory multiple myeloma.

Selected Publications:

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Segab M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM: Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial Lancet 387 (10027): 1551-60,2016.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritits E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jaganath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Laheurta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, San Miguel JF: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 15 (12): e538-48,2014.

Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, Olson SW: Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis J Clin Oncol 32 (25): 2699-704,2014.

Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA, Weiss BM: Classifying ultra-high risk smoldering myeloma Leukemia 29 (3): 751-3,2015.

Weiss BM: Multiethnic myeloma Blood 121 (16): 3062-4,2013.

Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, Drayson MT, Dispenzieri A, Leung N; International Kidney and Monoclonal Gammopathy Research Group.: How I treat monoclonal gammopathy of renal significance (MGRS) Blood 122 (22): 3583-90,2013.

Minter AR, Simpson H, Weiss BM, Landgren O: Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities. Seminars in Hematology 48 (1): 55-65,2011.

Weiss BM, Minter A, Abadie J, Howard R, Ascencao J, Schechter GP, Kuehl M, Landgren O: Patterns of Monoclonal Immunoglobulins and Serum Free Light Chains Are Significantly Different in African-American Compared to Caucasian MGUS Patients. American Journal of Hematology 86 (6): 475-8,2011.

Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, McGlynn KA, Landgren O: Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116 (25): 5501-5506,2010.

Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM: A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113 (22): 5418-5422,2009.

Academic Contact Info

Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-153
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 615-5853
Fax: (215) 615-5887
Patient appointments: 800-789-PENN (7366)

Related Links